January 11, 2011
Pharmaceutical company Novo Nordisk Inc. has asked a judge to toss antitrust claims made by generic-drug maker Paddock Laboratories Inc. in an infringement dispute over Novo's diabetes drug Prandin, saying it is not to blame for Paddock's delayed market entry.
December 01, 2010
The federal judge overseeing Novo Nordisk Inc.'s patent infringement suit against Paddock Laboratories Inc. over diabetes drug Prandin has determined that the U.S. District Court for the District of Minnesota has priority to hear the parties' dispute over whether Novo has unlawfully monopolized the market for the drug.